Literature DB >> 10543282

A cost analysis on the pattern of asthma prescribing in the UK.

R G Neville1, M G Pearson, N Richards, J Patience, S Sondhi, B Wagstaff, N Wells.   

Abstract

There is a need to establish the proportion of adult asthmatics at each step of the recommended asthma management guidelines, the cost of their prescribed treatment, and a revised cost of treatment assuming patients who were suboptimally controlled were moved up a step. Actual prescription and cost figures and a theoretical projection of an ideal scenario was calculated from a sample of general practices in Great Britain from the Doctors Independent Network. They comprised 102 nationally distributed practices and 17,206 adult patients with a diagnosis of, and prescription related to, asthma recorded between October 1993 and March 1994. Ninety-one per cent of patients received treatment within a recognized step of the guidelines. Of these, 80% were at steps 1 and 2. Employing excess inhaled beta-agonist use as a proxy for control of asthma, between 55% and 69% of patients at Steps 1-3 should receive treatment at a higher step. This could lead to an increased expenditure of up to Pound Sterling 4.66 per adult patient per month. This would imply a rise in the annual UK cost of antiasthma prescriptions for adults from Pound Sterling 388m to a possible Pound Sterling 533m. The United Kingdom Government audit commission has suggested that current expenditure on asthma treatment appears to be insufficient. Using an entirely different approach this study has confirmed that a significant increase in asthma prescribing costs is likely to be needed if optimal control of asthma is to be achieved.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543282     DOI: 10.1034/j.1399-3003.1999.14c20.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

Review 1.  Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD).

Authors:  J Wright; D Brocklebank; F Ram
Journal:  Qual Saf Health Care       Date:  2002-12

Review 2.  Management of asthma in adults: current therapy and future directions.

Authors:  R H Green; C E Brightling; I D Pavord; A J Wardlaw
Journal:  Postgrad Med J       Date:  2003-05       Impact factor: 2.401

3.  Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.

Authors:  F S Ram; J Wright; D Brocklebank; J E White
Journal:  BMJ       Date:  2001-10-20

4.  The effect of inhaled budesonide and formoterol on bronchial remodeling and HRCT features in young asthmatics.

Authors:  Firuz Capraz; Erdogan Kunter; Hakan Cermik; Ahmet Ilvan; Suheyl Pocan
Journal:  Lung       Date:  2007-03-28       Impact factor: 2.584

5.  Factors affecting UK primary-care costs of managing patients with asthma over 5 years.

Authors:  Roben Dasgupta; Julian F Guest
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

6.  Real-life prescribing of asthmatic treatments in UK general practice over time using 2014 BTS/SIGN steps.

Authors:  Alicia Gayle; Abigail Tebboth; Marie Pang; Florent Guelfucci; Ramzi Argoubi; Steven Sherman; Vincent Mak
Journal:  NPJ Prim Care Respir Med       Date:  2019-07-11       Impact factor: 2.871

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.